TRAILBLAZING COLLABORATION TO REDEFINE PRECISION MEDICINE  

EGE Bio, a trailblazer in precision medicine through epigenetic gene editing, and Turquoise Biotechnologies, a leader in exosome-based targeted drug delivery, proudly announce a transformative partnership that promises to revolutionize targeted therapeutics. This collaboration unites the cutting-edge expertise of both companies to deliver groundbreaking solutions for autoimmune diseases and beyond, creating a new era in precision healthcare.

SYNERGISTIC EXPERTISE: MERGING INNOVATION FOR TRANSFORMATIVE IMPACT

At EGE.bio, we harness the collaborative power of interdisciplinary expertise to break new ground in precision medicine. By integrating cutting-edge technologies such as biomarkers, RNA interference (RNAi), CRISPR, and targeted drug delivery systems, we are positioned to create innovative therapeutic strategies that enhance patient care. This synergistic approach allows us to address complex medical challenges comprehensively, leading to breakthrough solutions that promise transformative impacts on patient outcomes. Through collaboration and shared insights, we are redefining the landscape of healthcare, enabling a future where precision medicine is accessible and effective for all.  

EGE Bio harnesses advanced technologies such as CRISPR gene editing and RNA interference (RNAi) to target the root causes of autoimmune diseases. By combining early detection with genetic precision and safe delivery systems, EGE Bio pioneers durable treatments designed to deliver true cures, not just symptom relief.  

Turquoise Biotechnologies brings unmatched innovation in exosome-based delivery systems. Their proprietary platforms—ExoAim, ExoMed, and ExoGene—enable precise and efficient delivery of therapeutic agents such as RNA, DNA, and drugs directly to diseased cells. This approach enhances efficacy while drastically minimizing side effects, setting a new standard for therapeutic precision.

A MESSAGE FROM LEADERSHIP: DEFINING THE FUTURE OF TARGETED THERAPIES

"This partnership is a monumental leap toward changing how we approach autoimmune diseases and targeted therapeutics as a whole," said Reem Mahrat, CEO of EGE Bio. "At EGE Bio, we believe in curing diseases at their root. By aligning our expertise in gene editing with Turquoise Biotechnologies’ revolutionary delivery systems, we are creating therapies that don’t just treat symptoms but offer real, lasting solutions.  

"This is more than a partnership—it’s a commitment to patients who have waited too long for better care. Together, we are reshaping the future of precision medicine, and I am proud to lead EGE Bio in this transformative journey." 

Dr. Majid Ghoddusi, Founder and CEO of Turquoise Biotechnologies, echoed this enthusiasm: "Collaborating with EGE Bio allows us to push the boundaries of what’s possible in targeted therapeutics. The synergy between our teams is extraordinary, and together, we aim to redefine standards in therapeutic precision and effectiveness." 

Key Focus Areas of the Partnership.

1. Transforming Autoimmune Disease Care  

The collaboration combines EGE Bio’s gene editing technologies with Turquoise Biotechnologies’ exosome delivery platforms to create therapies that precisely target autoimmune diseases at their genetic origins.  
2. Broadening Scope to Oncology and Rare Diseases  

In addition to autoimmune diseases, the partnership seeks to tackle areas like oncology, leveraging the precision of their platforms to target tumors with minimal collateral damage, and rare diseases, where traditional treatments often fall short.  

3. Advancing Safety and Precision  

The partnership prioritizes the development of therapies that specifically target diseased cells, significantly reducing off-target effects and enhancing overall safety.

DRIVING IMPACT: A SHARED VISION FOR INNOVATION  

By merging gene editing with next-generation delivery technologies, this partnership reflects an unwavering commitment to transforming healthcare through innovation. Together, EGE Bio and Turquoise Biotechnologies aim to address unmet medical needs, improve patient outcomes, and deliver therapies that bring real hope to millions.  

LOOKING AHEAD: LEADING THE CHARGE FOR A NEW ERA IN PRECISION MEDICINE  

EGE Bio and Turquoise Biotechnologies are not just partnering to develop better treatments—they are uniting to redefine what is possible in medicine. By leveraging their collective expertise, they are creating a future where diseases are precisely targeted, effectively treated, and, ultimately, cured.  

As this partnership unfolds, the companies remain steadfast in their commitment to delivering breakthrough innovations that address the world’s most pressing healthcare challenges. Together, they are building a legacy of transformation in precision medicine, offering patients a new standard of care and renewed hope for a healthier tomorrow.